Explore the words cloud of the CRYDIS project. It provides you a very rough idea of what is the project "CRYDIS" about.
The following table provides information about the project.
Coordinator |
KOBENHAVNS UNIVERSITET
Organization address contact info |
Coordinator Country | Denmark [DK] |
Project website | https://pharmacy.ku.dk/research/pharmaceutical-physical-analytical-chemistry/crydis/ |
Total cost | 216˙000 € |
EC max contribution | 216˙000 € (100%) |
Programme |
1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge) |
Code Call | H2020-MSCA-RISE-2014 |
Funding Scheme | MSCA-RISE |
Starting year | 2015 |
Duration (year-month-day) | from 2015-01-01 to 2018-12-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | KOBENHAVNS UNIVERSITET | DK (KOBENHAVN) | coordinator | 130˙500.00 |
2 | UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK | IE (Cork) | participant | 31˙500.00 |
3 | PFIZER LIMITED | UK (SANDWICH) | participant | 27˙000.00 |
4 | PARAYTEC LIMITED | UK (YORK) | participant | 18˙000.00 |
5 | PION INC.(UK) LTD | UK (FOREST ROW) | participant | 9˙000.00 |
The CRYDIS exchange programme will establish and support international and inter-sectoral transfer of knowledge and expertise in pharmaceutical and instrument science between several EU research institutes and industrial companies. It will also enhance understanding of the value of inter-sectoral exchange mechanisms for taking research to market. CRYDIS undertakes innovative, collaborative research on the clinically-important topic of dissolution of drug substance particles in bio-relevant media and the undesired subsequent nucleation and re-precipitation of the drug prior to its absorption. Using innovative advances in UV imaging technology, CRYDIS investigates the utility of novel dissolution assays as key tools to obtain fundamental data on the mechanism and kinetics of undesired nucleation and re-precipitation during or following dissolution, a significant problem for the pharmaceutical industry which struggles to obtain sufficient exposure to poorly soluble drug substances to ensure an effective dose is absorbed by the patient. The key technologies in this proposal offer a step change in capability and functionality, offering the potential to undertake more detailed studies of the dissolution/re-precipitation processes relevant to pharmaceutical materials. Access to this key technology and the further development of its capability offers the potential for breakthroughs in development of process understanding and of robust and widely applicable protocols. Additional value is brought to CRYDIS through close working with synergistic European networks, leveraging a greater knowledge input and impact outreach. Running parallel with the science programme, an innovation management work-package analyses effectiveness of the exchange mechanism in building a shared culture, transferring knowledge and developing understanding of processes that drive a product to market. The outcomes of this will be used to advise and drive potential future exchange activities.
Technical note on new capabilities | Documents, reports | 2019-10-28 17:20:03 |
Literature publications for D2.1-D2.4 | Documents, reports | 2019-10-28 17:20:03 |
Operating parameters for imaging & variability | Demonstrators, pilots, prototypes | 2019-10-28 17:20:03 |
Technical data on nucleation rates | Documents, reports | 2019-10-28 17:20:03 |
Screening assay for precipitation inhibitors | Demonstrators, pilots, prototypes | 2019-10-28 17:20:03 |
Dissolution testing guidelines for UV/Raman | Documents, reports | 2019-10-28 17:20:03 |
Literature publications for D3.1 & D3.2 | Documents, reports | 2019-10-28 17:20:03 |
ATR-(FTIR) & turbidity studies | Demonstrators, pilots, prototypes | 2019-10-28 17:20:02 |
pH-UV imaging method | Demonstrators, pilots, prototypes | 2019-10-28 17:20:02 |
UV imaging data validation | Demonstrators, pilots, prototypes | 2019-10-28 17:20:02 |
Technical report on approaches to SDI | Documents, reports | 2019-10-28 17:20:02 |
Optimised UV/Raman experiments | Demonstrators, pilots, prototypes | 2019-10-28 17:20:02 |
Prototype light microscopy – UV imaging assay | Demonstrators, pilots, prototypes | 2019-10-28 17:20:02 |
Technical report on new capabilities | Documents, reports | 2019-10-28 17:20:02 |
Take a look to the deliverables list in detail: detailed list of CRYDIS deliverables.
year | authors and title | journal | last update |
---|---|---|---|
2017 |
Peter Madelung, Poul Bertelsen, Jette Jacobsen, Anette Müllertz, Jesper Østergaard Dissolution enhancement of griseofulvin from griseofulvin-sodium dodecyl sulfate discs investigated by UV imaging published pages: 516-522, ISSN: 1773-2247, DOI: 10.1016/j.jddst.2017.05.010 |
Journal of Drug Delivery Science and Technology 39 | 2019-10-28 |
2018 |
Maria Doreth, Korbinian Löbmann, Petra Priemel, Holger Grohganz, Robert Taylor, René Holm, Heidi Lopez de Diego, Thomas Rades Influence of PVP molecular weight on the microwave assisted in situ amorphization of indomethacin published pages: 62-69, ISSN: 0939-6411, DOI: 10.1016/j.ejpb.2017.10.001 |
European Journal of Pharmaceutics and Biopharmaceutics 122 | 2019-10-28 |
2018 |
Jesper Østergaard UV imaging in pharmaceutical analysis published pages: 140-148, ISSN: 0731-7085, DOI: 10.1016/j.jpba.2017.07.055 |
Journal of Pharmaceutical and Biomedical Analysis 147 | 2019-10-28 |
2016 |
Sabrine S. Jensen, Henrik Jensen, David M. Goodall, Jesper Østergaard Performance characteristics of UV imaging instrumentation for diffusion, dissolution and release testing studies published pages: 113-123, ISSN: 0731-7085, DOI: 10.1016/j.jpba.2016.08.018 |
Journal of Pharmaceutical and Biomedical Analysis 131 | 2019-10-28 |
2017 |
Yu Sun, Jesper Østergaard Application of UV Imaging in Formulation Development published pages: 929-940, ISSN: 0724-8741, DOI: 10.1007/s11095-016-2047-5 |
Pharmaceutical Research 34/5 | 2019-10-28 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CRYDIS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CRYDIS" are provided by the European Opendata Portal: CORDIS opendata.
RELIABLE TECHNOLOGIES AND MODELS FOR VERIFIED WIRELESS BODY-CENTRIC TRANSMISSION AND LOCALIZATION
Read MoreOutcomes of Patients’ Evidence With Novel, Do-It-Yourself Artificial Pancreas Technology
Read MoreIdentifying Marginal Lands in Europe and strengthening their contribution potentialities in a CO2sequestration strategy
Read More